by Raynovich Rod | Nov 12, 2013 | Macro
Isn’t A “Long Only” Hedge Fund A Mutual Fund? The news from Monday’s November 11 Wall Street Journal on p C1 is that hedge funds who are shorting stocks are underperforming the market and most mutual finds. In this article, Juliet Chung points...
by Raynovich Rod | Aug 28, 2013 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
But Uncertainty Clouds Intermediate Term Economic Outlook: Oil prices, Emerging Markets, Russia and the FED Concerns about another Middle East war and a spike in oil prices waned a bit today but many “undertoads” remain such as weak economic data, taper...
by Raynovich Rod | Aug 22, 2013 | Macro
Update 8/26 Best idea on securities exchanges: Randall W.Forsyth in his Barron’s Up and Down Wall Street column recommends that the NASDAQ and NYSE are put under the watchful eye of the NSA. And while we are on “big data” there is news that Amazon...
by Raynovich Rod | Aug 21, 2013 | Biopharmaceuticals, Macro
Very Strange Whipsaw Day Who is in charge of this market, humans or computers? Earlier: My biopharma screen has gone green. Maybe “taper light” scenario means buy biotech as macro and interest rates are not affected. More later but NASDAQ reversal...
by Raynovich Rod | Aug 18, 2013 | Biopharmaceuticals, Macro
Tempering, Tapering and Transition A mild sell-off shifted momentum to the bears last week as countercurrents and seasonality comes into play. Heavy vacations in August transition to Labor Day weekend, Jewish holidays then a pick up in trading by mid-September. Here...
by Raynovich Rod | Aug 15, 2013 | Biopharmaceuticals, Macro
Biotech Sector Momentum Quits-IBB at Support Level of $189 NASDAQ Off 1.73% to 3605 Have fund managers raised cash and gone on vacation? Moreover many weaker sectors have become leaders like gold, silver,materials and energy. Walmart and Cisco are leading the way...
by Raynovich Rod | Jul 18, 2013 | 2025 Rayno Biopharmaceuticals Portfolio, Macro
7/19 11:45a EDT Update -Correction Limited to Techs, Biotechs Surge Tech correction continues with XLK down 1.5% but more money finding its way into biotech “bubblet” with IBB ($195) up 1.6%.Leading sectors are energy, healthcare and industrial with...
by Raynovich Rod | Jul 10, 2013 | Macro
Run the Presses-Money That Is Buy Stocks, Bonds, Gold? It could be a knee jerk reaction but investors are bullish after Bernanke says economy still needs help from stimulative money policy. Low interest rate policies should continue. Futures rally with NASDAQ and...
by Raynovich Rod | Jun 27, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Bond Market Stabilizes A strong bond auction today for the 7 Year Treasury at an interest rate of 1.94% helped support the three day rally easing investor concerns about rising interest rates and liquidation of bonds. European and Japanese stocks were also up. Bond...
by Raynovich Rod | Jun 25, 2013 | Biopharmaceuticals, Clinical Diagnostics and Tools, Macro
Global Economic Picture Not Good-Healthcare A Laggard on Rally Day Strong housing and durable goods data supported the rally today taking the S&P up 0.95% and NASDAQ up 0.82%. Comments from the China’s Central Bank helped a recovery from a free fall in the...
